Automated, cost-effective production of mRNA vaccines as well as cell and gene therapeutics

“The system will enable automated, component-based, flexible and validatable production”

07-Nov-2023 - mRNA-based vaccines and gene/cell therapeutics open up new possibilities for medical practitioners in the fight against cancer and infectious or hereditary diseases. However, manufacturing these innovative pharmaceuticals is an expensive and time-consuming process. The Fraunhofer RNAuto ...

Merck Collaborates with Innovative Biotech to Support Establishment of First Vaccine Production Facility in Nigeria

15-Dec-2021 - Merck announced that it has signed an agreement with biotechnology company Innovative Biotech (IB) to design the manufacturing process for the first vaccine production facility in Nigeria. “We are committed to expanding access to life-saving and life-enhancing therapies to patients across the ...

Siemens and BioNTech expand their collaboration for global vaccine production

Joint creation of a vaccine production facility in Singapore

24-Jun-2021 - German biotechnology company BioNTech SE, based in Mainz, and Siemens intend to expand their strategic cooperation. The companies plan to intensify their collaboration for the rapid expansion and creation of production capacity for the Covid-19 vaccine. BioNTech has expressed its aim of ...

BioNTech to Establish Regional Headquarters for Southeast Asia and First mRNA Manufacturing Facility in Singapore

Planned state-of-the-art manufacturing site will support global supply of mRNA-based vaccines and therapeutics

12-May-2021 - BioNTech SE announced plans to expand its global footprint to Asia with the establishment of its Regional Headquarters for southeast Asia in Singapore. In addition to selecting Singapore as its future regional headquarters, BioNTech plans to establish a fully integrated mRNA manufacturing ...

Lonza and Moderna Enter New Agreement to Double Drug Substance Production for COVID-19 Vaccine in Visp

New agreement for three further production lines at Lonza’s site in Visp, Switzerland

29-Apr-2021 - Lonza announced the expansion of its collaboration with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to manufacture the drug substance for the COVID-19 Vaccine Moderna. The expanded collaboration provides for the installation of three additional drug ...

Start of production in record time: Evonik delivers first lipids from German facility to BioNTech today

Availability of COVID-19 vaccine to increase significantly

23-Apr-2021 - Evonik is helping to accelerate the production of the COVID-19 vaccine from Pfizer-BioNTech by suppling an essential component. Evonik is delivering first batches of the urgently needed lipids for the mRNA-based vaccine to BioNTech months earlier than planned. Specialists at Evonik’s Hanau site ...

IDT Biologika and Takeda support production of the Johnson & Johnson single-shot COVID-19 vaccine

18-Mar-2021 - IDT Biologika is now using capacities at its Dessau site previously reserved for Takeda Pharmaceutical Company’s dengue vaccine candidate to fill and package the single-shot COVID-19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. IDT and Takeda announced an ...

CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV

Anticipated production of up to 50 million doses by the end of 2021 and up to a further 200 million doses in 2022 at the Novartis’ manufacturing site in Kundl, Austria

05-Mar-2021 - CureVac N.V. and Novartis AG announced that they have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the start of production, technology transfers and test runs are already underway. Following final agreement, Novartis plans to ...

Evonik strengthens strategic partnership with BioNTech on COVID-19 vaccine

Establishment of additional lipid production in Germany for use with mRNA-based vaccines

12-Feb-2021 - Evonik is investing in the short-term expansion of its specialty lipids production which are essential for mRNA-based COVID-19 vaccines. Commercial lipid quantities are to be produced at Evonik’s Hanau and Dossenheim sites in Germany as early as the second half of 2021 as part of a strategic ...

KNAUER is expanding its business activities into the field of lipid nanoparticle production equipment

In connection with the development of mRNA-based vaccines against Corona, LNPs have shown to be a suitable delivery form

11-Dec-2020 - Lipid nanoparticles (LNPs) encapsulate and protect the delicate active ingredient and allow its transport to the target cells in the human body. This will be the first large-scale use of mRNA and lipid nanoparticles in vaccination history. KNAUER, the Berlin based manufacturer of high-tech ...